+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 6040923
Description Jump to:

Transthyretin Amyloidosis Treatment Market Growth & Trends

The global transthyretin amyloidosis treatment market size is anticipated to reach USD 16.53 billion by 2030. The market is projected to grow at a CAGR of 13.9% from 2025 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients’ need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the “Heart Hero” campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

Transthyretin Amyloidosis Treatment Market Report Highlights

  • By type, the ATTR-CM accounted for a leading share in 2024 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline
  • By therapy, the targeted therapy segment grabbed a dominant share in 2024 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM
  • By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2024 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs
  • By distribution channel, the hospital pharmacies captured the largest share in 2024 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis
  • North America region held the largest share in 2024 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region
  • The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapy
1.2.2. Type
1.2.3. Disease
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Transthyretin Amyloidosis Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Transthyretin Amyloidosis Treatment Market: Therapy Business Analysis
4.1. Therapy Market Share, 2024 & 2030
4.2. Therapy Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
4.4. Targeted Therapy
4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
4.4.2. Vyndaqel/ Vyndamax
4.4.2.1. Vyndaqel/ Vyndamax Market, 2018 - 2030 (USD Million)
4.4.3. Onpattro
4.4.3.1. Onpattro Market, 2018 - 2030 (USD Million)
4.4.4. Amvuttra
4.4.4.1. Amvuttra Market, 2018 - 2030 (USD Million)
4.4.5. Tegsedi
4.4.5.1. Tegsedi Market, 2018 - 2030 (USD Million)
4.4.6. Wainua
4.4.6.1. Wainua Market, 2018 - 2030 (USD Million)
4.5. Supportive Therapy
4.5.1. Supportive Therapy Market, 2018 - 2030 (USD Million)
4.6. Pipeline Therapy
4.6.1. Pipeline Therapy Market, 2018 - 2030 (USD Million)
Chapter 5. Transthyretin Amyloidosis Treatment Market: Type Business Analysis
5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. ATTR with Polyneuropathy (ATTR-PN)
5.4.1. ATTR with Polyneuropathy (ATTR-PN) Market, 2018 - 2030 (USD Million)
5.5. ATTR with Cardiomyopathy (ATTR-CM)
5.5.1. ATTR with Cardiomyopathy (ATTR-CM) Market, 2018 - 2030 (USD Million)
Chapter 6. Transthyretin Amyloidosis Treatment Market: Disease Business Analysis
6.1. Disease Market Share, 2024 & 2030
6.2. Disease Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
6.4. Hereditary Transthyretin Amyloidosis
6.4.1. Hereditary Transthyretin Amyloidosis Market, 2018 - 2030 (USD Million)
6.4.2. Polyneuropathy
6.4.2.1. Polyneuropathy Market, 2018 - 2030 (USD Million)
6.4.3. Cardiomyopathy
6.4.3.1. Cardiomyopathy Market, 2018 - 2030 (USD Million)
6.4.4. Mixed Type
6.4.4.1. Mixed Type Market, 2018 - 2030 (USD Million)
6.5. Wild Type Amyloidosis
6.5.1. Wild Type Amyloidosis Market, 2018 - 2030 (USD Million)
Chapter 7. Transthyretin Amyloidosis Treatment Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Specialty Pharmacies
7.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
7.6. Retail Pharmacies
7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.7. Online Pharmacies
7.7.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 8. Transthyretin Amyloidosis Treatment Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework
8.4.2.3. Competitive Insights
8.4.2.4. U.S. Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework
8.4.3.3. Competitive Insights
8.4.3.4. Canada Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Regulatory Framework
8.4.4.3. Competitive Insights
8.4.4.4. Mexico Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework
8.5.2.3. Competitive Insights
8.5.2.4. UK Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework
8.5.3.3. Competitive Insights
8.5.3.4. Germany Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework
8.5.4.3. Competitive Insights
8.5.4.4. France Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework
8.5.5.3. Competitive Insights
8.5.5.4. Italy Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework
8.5.6.3. Competitive Insights
8.5.6.4. Spain Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.7. Norway
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework
8.5.7.3. Competitive Insights
8.5.7.4. Norway Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.8. Denmark
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework
8.5.8.3. Competitive Insights
8.5.8.4. Denmark Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.9. Sweden
8.5.9.1. Key Country Dynamics
8.5.9.2. Regulatory Framework
8.5.9.3. Competitive Insights
8.5.9.4. Sweden Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework
8.6.2.3. Competitive Insights
8.6.2.4. Japan Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework
8.6.3.3. Competitive Insights
8.6.3.4. China Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework
8.6.4.3. Competitive Insights
8.6.4.4. India Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework
8.6.5.3. Competitive Insights
8.6.5.4. South Korea Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework
8.6.6.3. Competitive Insights
8.6.6.4. Australia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Regulatory Framework
8.6.7.3. Competitive Insights
8.6.7.4. Thailand Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework
8.7.2.3. Competitive Insights
8.7.2.4. Brazil Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework
8.7.3.3. Competitive Insights
8.7.3.4. Argentina Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework
8.8.2.3. Competitive Insights
8.8.2.4. South Africa Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework
8.8.3.3. Competitive Insights
8.8.3.4. Saudi Arabia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework
8.8.4.3. Competitive Insights
8.8.4.4. UAE Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework
8.8.5.3. Competitive Insights
8.8.5.4. Kuwait Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Pfizer Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Alnylam Pharmaceuticals, Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Ionis Pharmaceuticals
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. AstraZeneca
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Akcea Therapeutics
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. BridgeBio Inc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Intellia Therapeutics, Inc.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. SOM BIOTECH
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Oncopeptides AB
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Takeda Pharmaceutical Company Limited
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global transthyretin amyloidosis treatment market, by region, 2018 - 2030 (USD Million)
Table 4 Global transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 5 Global transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 6 Global transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 7 Global transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 8 North America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
Table 9 North America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 10 North America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 11 North America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 12 North America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 13 U.S. transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 14 U.S. transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 15 U.S. transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 16 U.S. transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 17 Canada transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 18 Canada transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 19 Canada transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 20 Canada transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 21 Mexico transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 22 Mexico transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 23 Mexico transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 24 Mexico transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Europe transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
Table 26 Europe transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 27 Europe transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 28 Europe transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 29 Europe transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 30 UK transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 31 UK transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 32 UK transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 33 UK transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Germany transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 35 Germany transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 36 Germany transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 37 Germany transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 38 France transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 39 France transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 40 France transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 41 France transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 42 Italy transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 43 Italy transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 44 Italy transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 45 Italy transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 46 Spain transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 47 Spain transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 48 Spain transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 49 Spain transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 Denmark transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 51 Denmark transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 52 Denmark transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 53 Denmark transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 54 Sweden transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 55 Sweden transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 56 Sweden transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 57 Sweden transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 58 Norway transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 59 Norway transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 60 Norway transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 61 Norway transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Asia Pacific transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 64 Asia Pacific transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 65 Asia Pacific transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 66 Asia Pacific transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 67 China transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 68 China transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 69 China transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 70 China transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 Japan transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 72 Japan transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 73 Japan transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 74 Japan transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 India transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 76 India transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 77 India transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 78 India transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 Australia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 80 Australia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 81 Australia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 82 Australia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 83 South Korea transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 84 South Korea transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 85 South Korea transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 86 South Korea transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 87 Thailand transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 88 Thailand transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 89 Thailand transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 90 Thailand transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 91 Latin America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
Table 92 Latin America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 93 Latin America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 94 Latin America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 95 Latin America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 96 Brazil transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 97 Brazil transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 98 Brazil transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 99 Brazil transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 100 Argentina transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 101 Argentina transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 102 Argentina transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 103 Argentina transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 109 South Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 110 South Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 111 South Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 112 South Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 117 UAE transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 118 UAE transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 119 UAE transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 120 UAE transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
Table 121 Kuwait transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
Table 122 Kuwait transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
Table 123 Kuwait transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
Table 124 Kuwait transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Transthyretin amyloidosis treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapy and type outlook (USD Million)
Fig. 10 Disease and distribution channel outlook (USD Million)
Fig. 11 Competitive landscape
Fig. 12 Transthyretin amyloidosis treatment market dynamics
Fig. 13 Transthyretin amyloidosis treatment market: Porter’s five forces analysis
Fig. 14 Transthyretin amyloidosis treatment market: PESTLE analysis
Fig. 15 Transthyretin amyloidosis treatment market: Therapy segment dashboard
Fig. 16 Transthyretin amyloidosis treatment market: Therapy market share analysis, 2024 & 2030
Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
Fig. 18 Vyndaqel/ Vyndamax market, 2018 - 2030 (USD Million)
Fig. 19 Onpattro market, 2018 - 2030 (USD Million)
Fig. 20 Amvuttra market, 2018 - 2030 (USD Million)
Fig. 21 Tegsedi market, 2018 - 2030 (USD Million)
Fig. 22 Wainua market, 2018 - 2030 (USD Million)
Fig. 23 Supportive therapy market, 2018 - 2030 (USD Million)
Fig. 24 Pipeline Therapy market, 2018 - 2030 (USD Million)
Fig. 25 Transthyretin amyloidosis treatment market: Type segment dashboard
Fig. 26 Transthyretin amyloidosis treatment market: Type market share analysis, 2024 & 2030
Fig. 27 ATTR with Polyneuropathy (ATTR-PN) market, 2018 - 2030 (USD Million)
Fig. 28 ATTR with Cardiomyopathy (ATTR-CM) market, 2018 - 2030 (USD Million)
Fig. 29 Transthyretin amyloidosis treatment market: Disease segment dashboard
Fig. 30 Transthyretin amyloidosis treatment market: Disease market share analysis, 2024 & 2030
Fig. 31 Hereditary transthyretin amyloidosis market, 2018 - 2030 (USD Million)
Fig. 32 Polyneuropathy market, 2018 - 2030 (USD Million)
Fig. 33 Cardiomyopathy market, 2018 - 2030 (USD Million)
Fig. 34 Mixed type market, 2018 - 2030 (USD Million)
Fig. 35 Wild type amyloidosis market, 2018 - 2030 (USD Million)
Fig. 36 Transthyretin amyloidosis treatment market: Distribution channel segment dashboard
Fig. 37 Transthyretin amyloidosis treatment market: Distribution channel market share analysis, 2024 & 2030
Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 39 Specialty pharmacies market, 2018 - 2030 (USD Million)
Fig. 40 Retail pharmacies market, 2018 - 2030 (USD Million)
Fig. 41 Online pharmacies market, 2018 - 2030 (USD Million)
Fig. 42 Transthyretin amyloidosis treatment market revenue, by region
Fig. 43 Regional marketplace: Key takeaways
Fig. 44 Regional marketplace: Key takeaways
Fig. 45 North America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 46 U.S. country dynamics
Fig. 47 U.S. transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 48 Canada country dynamics
Fig. 49 Canada transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 50 Mexico country dynamics
Fig. 51 Mexico transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 52 Europe transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 53 UK country dynamics
Fig. 54 UK transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 55 Germany country dynamics
Fig. 56 Germany transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 57 France country dynamics
Fig. 58 France transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 59 Italy country dynamics
Fig. 60 Italy transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 61 Spain country dynamics
Fig. 62 Spain transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 63 Norway country dynamics
Fig. 64 Norway transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 65 Sweden country dynamics
Fig. 66 Sweden transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 67 Denmark country dynamics
Fig. 68 Denmark transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 69 Asia Pacific transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 70 Japan country dynamics
Fig. 71 Japan transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 72 China country dynamics
Fig. 73 China transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 74 India country dynamics
Fig. 75 India transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 76 Australia country dynamics
Fig. 77 Australia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 78 South Korea country dynamics
Fig. 79 South Korea transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 80 Thailand country dynamics
Fig. 81 Thailand transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 82 Latin America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 83 Brazil country dynamics
Fig. 84 Brazil transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 85 Argentina country dynamics
Fig. 86 Argentina transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 87 MEA transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 88 South Africa country dynamics
Fig. 89 South Africa transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 90 Saudi Arabia country dynamics
Fig. 91 Saudi Arabia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 92 UAE country dynamics
Fig. 93 UAE transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 94 Kuwait country dynamics
Fig. 95 Kuwait transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
Fig. 96 Company categorization
Fig. 97 Company market position analysis
Fig. 98 Strategic framework

Companies Mentioned

  • Pfizer Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals
  • AstraZeneca
  • Akcea Therapeutics
  • BridgeBio Inc.
  • Intellia Therapeutics, Inc.
  • SOM BIOTECH
  • Oncopeptides AB
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.64 billion
Forecasted Market Value ( USD ) by 2030 $ 16.53 billion
Compound Annual Growth Rate13.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Transthyretin Amyloidosis Treatment Global Market Report 2024 - Product Image

Transthyretin Amyloidosis Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Transthyretin Amyloidosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 179 Pages
  • Global
From
Transthyretin Amyloidosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Transthyretin Amyloidosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2024 - Product Image

Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Amyloidosis Treatment - Global Strategic Business Report - Product Image

Amyloidosis Treatment - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.